Successful long-term management of recurrent focal segmental glomerulosclerosis after kidney transplantation with costimulation blockade
Muehlbacher T, Amann KU, Mahling M, Nadalin S, Heyne N, Guthoff M (2021)
Publication Type: Journal article, Editorial
Publication year: 2021
Journal
Book Volume: 14
Pages Range: 1691-1693
Journal Issue: 6
DOI: 10.1093/ckj/sfaa267
Abstract
Recurrence of primary focal segmental glomerulosclerosis (FSGS) occurs in up to 50% of patients after kidney transplantation and is associated with poor allograft outcome. Novel therapeutic concepts directly target podocyte function via B7-1 with inconsistent response. We present the case of a 19-year-old patient with recurrent primary FSGS early after living donor kidney transplantation. Plasmapheresis and rituximab did not induce remission. Repetitive abatacept administration was able to achieve partial remission. Maintenance immunosuppression was subsequently switched to a belatacept-based calcineurin inhibitor-free immunosuppression, resulting in sustained complete remission with excellent allograft function throughout a follow-up of >56months.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Muehlbacher, T., Amann, K.U., Mahling, M., Nadalin, S., Heyne, N., & Guthoff, M. (2021). Successful long-term management of recurrent focal segmental glomerulosclerosis after kidney transplantation with costimulation blockade. Clinical Kidney Journal, 14(6), 1691-1693. https://doi.org/10.1093/ckj/sfaa267
MLA:
Muehlbacher, Thomas, et al. "Successful long-term management of recurrent focal segmental glomerulosclerosis after kidney transplantation with costimulation blockade." Clinical Kidney Journal 14.6 (2021): 1691-1693.
BibTeX: Download